Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;161(5):1657-1669.
doi: 10.1053/j.gastro.2021.07.049. Epub 2021 Sep 20.

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease

Fasiha Kanwal  1 , Jay H Shubrook  2 , Leon A Adams  3 , Kim Pfotenhauer  4 , Vincent Wai-Sun Wong  5 , Eugene Wright  6 , Manal F Abdelmalek  6 , Stephen A Harrison  7 , Rohit Loomba  8 , Christos S Mantzoros  9 , Elisabetta Bugianesi  10 , Robert H Eckel  11 , Lee M Kaplan  12 , Hashem B El-Serag  1 , Kenneth Cusi  13
Affiliations
Review

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease

Fasiha Kanwal et al. Gastroenterology. 2021 Nov.

Abstract

Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.gastro.org. Scan this QR code to be taken directly to the website.Nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common, currently affecting approximately 37% of US adults. NAFLD is most often managed in primary care or endocrine clinics, where clinicians must determine which patients might benefit from secondary care to address hepatic manifestations, comorbid metabolic traits, and cardiovascular risks of the disease. Because NAFLD is largely asymptomatic, and because optimal timing of treatment depends on accurate staging of fibrosis risk, screening at the primary care level is critical, together with consistent, timely, evidence-based, widely accessible, and testable management processes. To achieve these goals, the American Gastroenterological Association assembled a multidisciplinary panel of experts to develop a Clinical Care Pathway providing explicit guidance on the screening, diagnosis, and treatment of NAFLD. This article describes the NAFLD Clinical Care Pathway they developed and provides a rationale supporting proposed steps to assist clinicians in diagnosing and managing NAFLD with clinically significant fibrosis (stage F2-F4) based on the best available evidence. This Pathway is intended to be applicable in any setting where care for patients with NAFLD is provided, including primary care, endocrine, obesity medicine, and gastroenterology practices.

Keywords: Clinical Care Pathway; Liver Disease; NAFLD; NASH; Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Screening for advanced fibrosis related to NAFLD/NASH.
Figure 2.
Figure 2.
Evaluate for other forms of liver disease.
Figure 3.
Figure 3.
Management of NAFLD/NASH.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lomonaco R, Godinez Leiva E, Bril F, et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care 2021;44:399–406. - PMC - PubMed
    1. Ciardullo S, Monti T, Perseghin G. High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care 2021;44:519–525. - PubMed
    1. Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol 2021;75:284–291. - PubMed
    1. Wong CR, Lim JK. The association between nonalcoholic fatty liver disease and cardiovascular disease outcomes. Clin Liver Dis (Hoboken) 2018;12:39–44. - PMC - PubMed
    1. Younossi ZM, Stepanova M, Rafiq N, et al. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. Hepatol Commun 2017;1:421–428. - PMC - PubMed

Publication types

MeSH terms